Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Gama-Cyclodextrin BP EP USP Pharma Grade tells its story through both its structure and function. This raw material comes from the family of cyclodextrins, a group of cyclic oligosaccharides formed by enzyme conversion of starch. Structurally, it consists of eight glucopyranose units linked by α-1,4 glycosidic bonds, winding together into a toroidal ring with a hydrophobic internal cavity and a hydrophilic exterior. Few people outside pharma labs get to see the unique transition of Gama-Cyclodextrin from dense, off-white solid flakes to a fine crystalline powder, sometimes shaped into pearls or granules, depending on processing. In my work, seeing the subtle shimmer of a fine batch fresh out of drying always gives a sense of the careful handling required for pharmaceutical quality.
This compound earns its place in pharmaceutical development through properties that make it more than just another white powder. With a molecular formula of C48H80O40 and a molar mass near 1297.12 g/mol, Gama-Cyclodextrin stands out for its dense cyclized structure. In the palm, it feels almost silky, packing a surprisingly high bulk density for its apparent airiness, around 0.55 g/cm³, measurable in the lab through precise volumetric procedures. The melting point sits well above 200°C, showing real resilience under heat, though its solubility in water—about 200 g/L at room temperature—shows why it performs well as a complexation agent in drug delivery. Through my own use, finding how effortlessly it dissolves, forming clear solutions for test batches or pilot scaleups, always highlights its pharmaceutical value, whether used as a carrier or stabilizer.
A key reason pharma firms across Europe, Asia, and the Americas turn to Gama-Cyclodextrin comes down to safety and versatility. This cyclodextrin acts as a functional excipient, forming inclusion complexes that mask nasty tastes, improve active ingredient stability or increase drug solubility for oral, topical, and even injectable medicines. Its broad acceptance in major pharmacopeias, including BP, EP, and USP, rests on solid toxicology data: studies show low acute and chronic toxicity, with the compound classified as non-hazardous for standard handling, underlined by a lack of reproductive toxicity, carcinogenic, or mutagenic effects when used in regulated doses. In my hands-on work with raw materials, Gama-Cyclodextrin offers a welcome break from long stretches in the safety gear locker—still, standard chemical hygiene applies, since fine dust can irritate mucous membranes if airborne at scale.
Consistency and traceability stand as pillars in the pharmaceutical world, and Gama-Cyclodextrin lives up to those standards through strict specifications. Typical assays demand purity above 98.0%, minimal moisture content—usually less than 11%—and a residual solvent limit well within ICH guidelines. Infrared spectrometry confirms molecular structure, while chromatographic methods check for related substances and oligomeric impurities. The HS Code for Gama-Cyclodextrin is generally 3505.10, identifying it among dextrins and other modified starches, which streamlines global shipment and customs classification. Each batch often includes a full certificate of analysis: microbial limits, residual solvents, heavy metals—all checked and double-checked. My past audits for ingredient traceability taught me the importance of those details, especially when a hiccup at customs or a missing document can delay a full production run by weeks or more.
From a handling standpoint, Gama-Cyclodextrin tends to arrive as a solid, often packed in multiwall polyethylene or paper drums for bulk orders. Some suppliers offer finer powder grades, optimized for quick dispersal in process tanks, avoiding clumping or bridging—a detail that saves time during scaleups and pilot trials. Pearls or pellets sometimes appear in specialty shipments, usually when ease of metering or slow release becomes vital for specific formulations. Prepared aqueous solutions, standardized to a set concentration, streamline R&D or high-throughput screening, although shelf life and transport weight become concerns. In past formulation experiments, switching between powder and pearl forms made a difference in blending time and final product uniformity, forcing one to pay attention to the smallest changes in raw material presentation.
Discussion around new excipients often circles back to questions of safety, not just for users but the broader environment as well. Gama-Cyclodextrin breaks down through enzymatic action after ingestion, forming glucose, handled by normal metabolic pathways, setting it apart from many synthetic excipients that linger in waste streams. Its lack of hazardous breakdown products and proven absence of environmental persistence make it less of a concern under new EU REACH guidelines or similar US EPA frameworks; in work with environmental audits, few excipients score as well. Even so, the potential for inhalation issues remains where dust controls lack rigor, calling for simple, cost-effective engineering like local exhaust ventilation or sealed transfer systems in production environments.
Every new raw material offers a path for improvement. Producers continue working on tighter purity thresholds, improved bulk density for easier handling, and customized granulometry to meet demanding pharma workflows. Solubility tuning stands as a current research focus, easing scale-up hurdles and formulation bottlenecks. Better batch traceability through digital chain-of-custody and advanced analytics could raise confidence for regulators and patients alike. From years spent in scale-up and validation, I can say that these small steps often outpace headline-grabbing innovations, making the path smoother from bench to bedside for any finished drug that uses Gama-Cyclodextrin as its silent workhorse.
Chengguan District, Lanzhou, Gansu, China
